What You Should Know:

您应该知道：

–

–

PathAI

PathAI

, a provider of

，提供

AI-powered

AI供电

pathology solutions, today announced the launch of

病理学解决方案，今天宣布推出

PathAssist Derm

PathAssist 皮肤

, an innovative tool designed to streamline the analysis of skin lesions.

，这是一种创新工具，旨在简化皮肤病变的分析。

– Available now on the AISight® Image Management System (IMS), this research tool automates specimen orientation and identification, enabling pathologists to review samples more efficiently and accurately.

–此研究工具现已在AISight®图像管理系统（IMS）上提供，可自动进行样本定位和识别，使病理学家能够更有效、更准确地检查样本。

PathAssist Derm Capabilities

PathAssist真皮功能

PathAssist Derm is the latest addition to PathAI’s suite of AI-powered solutions available on the AISight® IMS. This comprehensive platform provides pathologists with a range of tools to streamline their workflows and improve diagnostic accuracy. PathAssist Derm offers several key capabilities:

PathAssist Derm是AISight®IMS上提供的PathAI人工智能解决方案套件的最新补充。这个综合平台为病理学家提供了一系列工具，以简化其工作流程并提高诊断准确性。

Automated Specimen Orientation:

自动样品定位：

Eliminates the need for manual orientation of glass slides, saving pathologists valuable time and reducing the risk of errors.

无需手动定位载玻片，节省了病理学家宝贵的时间并降低了出错的风险。

Lesion Identification:

病变识别：

Predicts the presence of 17 different skin lesion entities, including common and rare conditions, aiding in diagnosis and research.

预测17种不同皮肤病变实体的存在，包括常见和罕见疾病，有助于诊断和研究。

Detailed Measurements:

详细测量：

Provides precise measurements of lesion size and characteristics, facilitating quantitative analysis.

提供病变大小和特征的精确测量，便于定量分析。

“Skin cancer remains the most prevalent cancer worldwide, with over 1.5 million new cases diagnosed annually, which are associated with 60,000 deaths from melanoma alone,” said Andrew Beck, Co-Founder & CEO of PathAI. “These statistics present a critical opportunity for innovation in skin cancer research, both in the diagnostic and therapeutic realms.

PathAI联合创始人兼首席执行官安德鲁·贝克（AndrewBeck）表示：“皮肤癌仍然是全球最普遍的癌症，每年诊断出150多万例新病例，仅黑色素瘤就导致6万人死亡。”。“这些统计数字为诊断和治疗领域的皮肤癌研究创新提供了关键机会。

Our goal with PathAssist Derm is to provide researchers with a scalable tool that enhances dermatopathology research through AI-enabled lesion characterization and workflow efficiency, as part of our overall vision to improve patient outcomes with AI-powered pathology.”.

我们使用PathAssist Derm的目标是为研究人员提供一个可扩展的工具，通过AI启用的病变表征和工作流程效率来增强皮肤病理学研究，作为我们整体愿景的一部分，以改善AI驱动的病理学患者的预后。”。

PathAI will be presenting performance results for PathAssist Derm at the upcoming USCAP meeting in March 2025 and is actively partnering with laboratories to further investigate the tool’s impact on efficiency and diagnostic accuracy.

PathAI将在2025年3月即将举行的USCAP会议上介绍PathAssist Derm的性能结果，并与实验室积极合作，进一步调查该工具对效率和诊断准确性的影响。